You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha‐2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)—AGMT_CML 1
|
|---|---|
| Published in |
Hematological Oncology, August 2020
|
| DOI | 10.1002/hon.2786 |
| Pubmed ID | |
| Authors |
Sonja Heibl, Veronika Buxhofer‐Ausch, Stefan Schmidt, Gerald Webersinke, Thomas Lion, Gudrun Piringer, Thomas Kuehr, Dominik Wolf, Thomas Melchardt, Richard Greil, Josef Thaler |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Science communicators (journalists, bloggers, editors) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 15 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 15 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Lecturer | 2 | 13% |
| Student > Bachelor | 2 | 13% |
| Student > Ph. D. Student | 2 | 13% |
| Professor | 2 | 13% |
| Researcher | 2 | 13% |
| Other | 3 | 20% |
| Unknown | 2 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 33% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 20% |
| Psychology | 2 | 13% |
| Agricultural and Biological Sciences | 1 | 7% |
| Environmental Science | 1 | 7% |
| Other | 1 | 7% |
| Unknown | 2 | 13% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 September 2020.
All research outputs
#13,690,633
of 23,228,787 outputs
Outputs from Hematological Oncology
#527
of 1,186 outputs
Outputs of similar age
#201,049
of 400,170 outputs
Outputs of similar age from Hematological Oncology
#21
of 45 outputs
Altmetric has tracked 23,228,787 research outputs across all sources so far. This one is in the 39th percentile – i.e., 39% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,186 research outputs from this source. They receive a mean Attention Score of 3.9. This one has gotten more attention than average, scoring higher than 50% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 400,170 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 45 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.